Background: The availability of direct-acting antivirals (DAAs) has dramatically chan-
| INTRODUCTION
Hepatitis C virus (HCV) infection remains a major public health concern, with more than 100 million people chronically infected worldwide. 1 Chronic hepatitis C is associated with significant morbidity, mortality and economic burden. It can progressively lead to cirrhosis, liver failure and hepatocellular carcinoma (HCC) and is the most common indication for liver transplantation in USA and Europe. 2 At least six major HCV genotypes have been identified-genotype 1 accounts for about 46% of all infections worldwide, followed by genotypes 3 (30%) and genotype 2 (9%). 3 Genotypes 1-3 are prevalent worldwide, whereas, genotypes 4 and 5 are found mostly in Africa, and genotype 6 is principally prevalent in Asia. 4 The treatment of hepatitis C experienced a revolution in the past few years with the availability of DAAs beginning in 2014. [5] [6] [7] These drugs have increased the response rates and tolerability of treatment dramatically. Several new orally administered drugs have been approved with a larger spectrum of viral genotypes, shorter duration of treatment and can be prescribed without interferon (IFN), which was administered as an injection and associated with many adverse side effects. 8 Multiple phase 3 trials and real-world studies demonstrated that more than 90% of chronic infected patients can now achieve sustained viral response (SVR) with DAAs, an accepted surrogate for cure. [9] [10] [11] [12] [13] [14] [15] [16] [17] The enthusiasm of highly effective DAAs has been dampened by their price and budget impact of treating a large number of HCV-infected persons. Contrary to the recommendation of unrestricted HCV treatment by leading clinical societies, 18 several payers, both in and outside the USA added restrictions to the use of DAAs by limiting the drug to patients with advanced fibrosis stage or other risk factors. 19, 20 The reasons for such restrictions include limited budget to treat the infected population, lack of clarity on the cost-effectiveness of new DAAs in different settings, and a lack of prioritisation in addressing the HCV disease burden among policy makers. 20 Evidence-based cost-effectiveness analysis (CEA) of HCV treatment with DAAs can inform decisions regarding access to treatment. 21 A number of cost-effectiveness studies have been published recently that project long-term costs, benefits and cost-effectiveness of new DAAs. 21 However, substantial heterogeneity exists in these studies with respect to the price of DAAs, analysis perspective, time horizon and other HCV-related disease characteristics. These differences in assumptions could influence the cost-effectiveness results and conclusions. A prior systematic review synthesised the CEA of DAAs in HCV genotype 1 patients and evaluated the impact of various factors on the cost-effectiveness of DAAs. 22 However such information is not available for other HCV genotypes, which account for 54% of all HCV infections worldwide. Therefore, the objective of our study was to synthesise all available CEA studies in HCV genotypes 2-6, and to re-evaluate cost-effectiveness results for different subgroups and estimate the threshold drug prices below which HCV treatment would be deemed cost-effective and cost-saving. published from January 1st, 2011 to August 28th, 2016. We used terms related to "hepatitis C", "direct antiviral agents" and "economic
| METHODS
evaluations." Table S1 shows the search strategy for Medline (Ovid).
| Inclusion and exclusion criteria
Studies were included in our analysis if they were full-length and peer-reviewed original articles, and reported an economic model to estimate the cost-effectiveness of treating HCV patients with DAA regimens. We included all approved DAAs, including boceprevir (BOC) and telaprevir (TEL), simeprevir (SMV), paritaprevir, asunaprevir, ledipasvir (LDV), ombitasvir, sofosbuvir (SOF), daclatasvir (DCV), dasabuvir, velpatasvir (VEL), elbasvir and grazoprevir.
We excluded studies that (1) were not written in English, (2) did not measure health outcomes using quality-adjusted life-years (QALYs), (3) did not report the drug price separately from the total treatment costs, (4) reported a drug regimen that has not been approved by the Food and Drug Administration or recommended by a professional organisation, (5) did not report any results for genotype 2-6 patients or (6) only included HIV or HBV co-infected patients, post liver transplant patients or patients with other complications.
| Study selection
Two reviewers (TH and JC) screened the titles and abstracts of the unique citations independently and determined if they met the inclusion criteria. Any disagreements regarding whether or not a particular analysis fulfilled the initial inclusion criteria were resolved by discussion leading to consensus. We then retrieved the full-text of those relevant citations and excluded unsuitable analyses according to our exclusion criteria resulting in the final group of studies analysed.
| Data collection process and data items
We created a standardised data extraction For each analysis, we also estimated the threshold DAA price below which HCV treatment would be deemed cost-effective, ie, ICER is below the willingness-to-pay (WTP) threshold of $100 000-per-QALY, 28 and cost-saving, ie, ICER is less than $0. We used the following mathematical relationship between the price threshold and ICER:
Our search resulted in 469 unique studies. After 2-step screening, 10 studies presenting 92 ICERs were included in our analysis ( Figure 1 ). ICERs evaluated treatment-experienced patients. Table 2 lists the key modelling features related to cost-effectiveness analysis, and Table 3 summarises modelling approaches and assumptions of the included studies. All studies followed healthcare payer's perspective, and none of them considered treatment-as-prevention benefits or extrahepatic benefits of hepatitis C treatment. Detailed characteristics of the final 92 ICERs included in the analysis are summarised in Table S3 .
| Overview of studies and patient characteristics

| Region
Among the selected studies, 47 ICERs (51%) from five studies evaluated the cost-effectiveness of DAAs in the USA. These studies eval- 
| Treatment strategies
The following DAAs regimens were evaluated as primary interven- 
| Modelling features
Modelling features applied to evaluate the cost-effectiveness of HCV treatments can impact the results, therefore, we abstracted relevant modelling characteristics. All 92 ICERs were conducted from a healthcare payer's perspective. We also noted that nine of the 10 studies included costs of managing adverse events and other medical expenses, none of the studies included non-medical costs 3. Reviews, letters, editorials, etc.
Non-English abstracts.
Studies excluded (n = 62): 1. Not modeling work or not CEA (n = 1).
2. Not an original study (n = 3). 3. Not relevant to DAAs or did not compare DAAs to SOC (n = 9). 4. Included only HIV/HCV co-infected patients (n = 1). 5. Did not report total costs, total QALY, or ICER (n = 9).
6. Did not report DAA costs separately from total cost (n = 5). 7. Mixed genotype 1, 2, and 3 patietns or mixed therapy in the settings (n = 3).
8. Include only genotype 1 infection (n = 30). 9. Applied TEL to G2 patients, which was not approved by FDA (n = 1). Table 3 summarises all modelling assumptions of the extracted studies. We found that six of 10 studies used cohort-level state-transition models, and the remaining four used individual-level microsimulation models. Time horizon used in the models varied between 1 week and 1 year. Nine of the 10 studies reported results of both 1-way and probabilistic sensitivity analyses. All studies discounted future costs and QALYs, but the annual rates varied between 3% and 5%. Seven studies reported at least one method used for validation of model.
| Quality of reporting
We evaluated the quality of reporting of all included studies by each CHEERS methodological item ( Figure S1 ). Most studies adhered to the reporting guidelines. However, the following issues were identified: three studies did not provide adequate structured abstracts, [30] [31] [32] one study did not adequately present the study question and its relevant health policy concerns, 29 and three studies did not explore all characteristics of uncertainty associated with patient-level data or model parameters. 30, 31, 33 One study did not describe characteristics of the targeted population and subgroups, 34 one failed to report adequate measurements and valuation of preference based outcomes, 33 and one did not provide price dates or currency conversion. 35 
| Cost-effectiveness of DAAs
For each abstracted analysis, we re-estimated the ICER by varying the price of DAAs from $20 000 to $100 000, and summarised the results by plotting the percentage of ICERs that were less than $0-per-QALY gained (ie, cost-saving), between $0 and $100 000-per-QALY gained (ie, cost-effective), and more than $100 000-per-QALY gained (ie, not cost-effective) at a given price. Figure 2 We further analysed the results by presence of cirrhosis, prior treatment and region of the study. The cost-effectiveness of DAAs was similar irrespective of patients' cirrhosis status ( Figure 3A ,B) or prior treatment history ( Figure 3C,D 
| DISCUSSION
The launch of DAAs provides an opportunity to eradicate HCV infection worldwide; however, the price of DAAs and budget impact could become major barriers to treatment access. Due to competition, the pricing of HCV regimens continue to decrease. Several published studies have evaluated the long-term value and cost-effectiveness of DAAs for different subgroups of patients. In our study, we systematically reviewed 92 results from 10 studies evaluating HCV genotypes 2-5 treatment and summarised heterogeneity among studies with respect to cost of DAAs, patient characteristics and modelling approaches. We found that more than 90% of the analyses would conclude DAAs to be cost-effective for genotypes 2-5 at the discounted price of $40 000, irrespective of presence of cirrhosis, prior treatment history or the region of the study. Furthermore, we found that the listed price of DAAs ($539-$94 500) was substantially lower than the threshold price ($144 400-$225 000) at which they would be deemed cost-effective. 36 In contrast, the threshold price at which DAAs would be deemed cost-saving was in the range of $17 300-$25 400.
To our knowledge, our study is the first to synthesize the results of the published cost-effectiveness studies of DAAs for treatment in HCV genotypes 2-5. A previously published systematic review analysed the results of HCV genotype 1 only, one review summarised the cost-effectiveness of HCV screening, and another review focused on modelling approaches and did not evaluate economic results. 21, 22, 37 In this study, we focused on HCV genotypes 2-5 for multiple reasons. First, cost-effectiveness of HCV genotype 1 has been extensively studied in the past but no study systematically reviewed other genotypes-more than half of the hepatitis C infections have genotypes other than genotype 1, and an analysis on the value of DAAs for these genotypes is important in regions outside USA. Second, the first-generation DAAs-boceprevir and telaprevir, were only approved for HCV genotype 1; whereas it was only with the availability of second-generation DAAs, treatment for genotypes | 717 2-6 evolved beyond PEG-RBV. Finally, several modelling studies, especially evaluating the cost-effectiveness of non-genotype 1 were published after the publication of prior systematic reviews.
Moreover, we used a novel approach to present the cost-effectiveness results by providing the per cent of studies per ICER and performing subgroup analyses considering the drug price, patient's HCV genotype, prior treatment history, disease severity and the region of the analysis. The evidence from our study, which includes 92 results from 10 modelling studies, is more comprehensive and therefore could be considered superior to the results from any individual CEA study. Inclusion of these factors would require changing the cost-effectiveness perspective from payer to societal and a system-dynamic modelling approach such as agent-based modelling. 41 From our review, we believe further studies are needed. None of the published modelling studies evaluated the cost-effectiveness of DAAs in low-income countries, where generic DAAs are available.
Because many countries where generic DAAs are available would also have limited resources allocated to healthcare, cost-effectiveness data could provide evidence to allocate money for widespread HCV treatment in these countries. Second, cost-effectiveness data is needed for pan-genotype sofosbuvir-velpatasvir and several new DAAs that are expected to be become available in the near future.
Third, DAAs are shown to be effective in transplant patients; [42] [43] [44] however, their cost-effectiveness has been debated-different studies reached conflicting conclusions. [45] [46] [47] [48] F I G U R E 5 Box plots showing the median, 25th percentile, and 75th percentile price threshold at which treatment with DAAs is A, cost-effective using $100 000 willingness-to-pay threshold, and B, cost-saving, by presence of cirrhosis, prior treatment experience and origin of study. The median threshold price for DAAs to be deemed cost-effective varied between $142 500 and $390 100, which is substantially higher than the listed price of any DAA in the USA and elsewhere ($539-$94 500). The median threshold price for DAAs to be deemed cost-saving was between $15 900 and $24 200. DAA, direct-acting antiviral agents; QALY, quality-adjusted life-years; TN, treatment na€ ıve; TE, treatment experienced and jails. [52] [53] [54] Finally, cost-effectiveness of hepatitis C treatment in children should be evaluated as clinical data becomes available. 55 Our study has several limitations. First, we excluded CEA studies which failed to report drug cost separately and were not suitable for re-calculation. Second, we summarised cost-effectiveness results stratified by a limited number of factors including the price of DAAs, HCV genotype, presence of cirrhosis, and prior treatment history.
However, several other modelling parameters such as transition probabilities, discount rate, cost of health states could have added heterogeneity to the results, and controlling for these factors is beyond the scope of our study. However, given that the results remained consistent across studies, we believe our conclusions would remain robust. Third, the quality of our results may be impacted by the quality of the individual studies included. Therefore, we screened each study using the CHEERS statement, and found that the majority of studies met quality criteria. Also, our synthesis
was limited to what the included studies reported. Very few analyses included genotype 5 patients, and none included genotype 6
patients. We only summarized results for genotype 2-5 in this study.
Finally, we limited our analysis to cost-effectiveness of DAAs vs.
non-DAA containing regimens, such as PEG/RBV.
In conclusion, our systematic review and analysis of cost-effectiveness studies found that HCV treatment with DAAs is highly cost-effective in patients with HCV genotypes 2-5. Our analysis provides further evidence that widespread and timely HCV treatment would be an optimal strategy from both a public health and eco- 
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